Skip Navigation

Editorial Board

EDITOR-IN-CHIEF:

Professor Jean-Charles Soria

Villejuif, France

Jean-Charles Soria

Current Positions and Research Interests
Jean-Charles Soria is a Professor of Medecine and Medical Oncology at South-Paris University. He is a tenure-track and full-time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012.

Professor Soria is currently Chair of Drug Development Depatment at Gustave Roussy Cancer Center in Paris and is a member of the lung cancer unit with a focus on targeted therapies. His main research interests are: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medecine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria was a member of ESMO Executive Committee from 2008 to 2009, and has served as an ASCO committee member since 2006. He was the scientific chairman of the ECCO-ESMO 2011 meeting that was held in Stockholm in 2011. He has contributed to over 340 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology. He has been appointed as Editor in Chief of Annals of Oncology for the period 2014-2018.

Declaration of Interests
Professor Soria has acted as a consultant for AstraZeneca, Amgen, GSK, EOS, Sanofi, Servier Genentech, Roche, Novartis and Lilly.

ASSOCIATE EDITORS

Urogenital tumors

G. Attard

Sutton, UK

Attard

Current Positions and Research Interests
Dr Attard is a Cancer Research UK clinician scientist and consultant medical oncologist at The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London in 2010. His main research interest is the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and has led on the early clinical development of abiraterone acetate, a novel inhibitor of CYP17. He is a co-author of more than 70 peer-reviewed manuscripts and has published several important papers on advanced prostate cancer. He also sits on a number of advisory boards.Dr Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. He devotes the majority of his time to academic research, both in the laboratory, investigating novel therapies for the treatment of prostate cancer, and in clinical trial research.

Declaration of Interests
Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Dr Attard has received consulting fees and travel support from Janssen-Cilag, Veridex, Roche/Ventana, Astellas, Novartis, Millennium Pharmaceuticals and Abbott Laboratories, speakers fees from Janssen, Ipsen, Takeda and Sanofi-Aventis, and grant support from AstraZeneca and Genentech. He is also on The ICR rewards to inventors list of abiraterone acetate.

M. De Santis

Vienna, Austria

DeSantis

Current Positions and Research Interests
Maria De Santis is a faculty member and lecturer in Oncology and Internal Medicine at the 3rd Medical Department – Center of Oncology and Haematology, Kaiser Franz Josef-Spital, SMZ Süd, Vienna, Austria. She is also chair of the genitourinary cancer service at the same institution. From 1982 to 1988 Maria De Santis studied at the Vienna University Medical School, obtaining her MD Diploma, in 1997 she received her approbation for Internal Medicine and in 1999 for Haematology and Oncology by the Austrian Medical Association. In 2008 she completed her habilitation for Internal Medicine (Associate Professor) at the Paracelsus Medical University in Salzburg, Austria. Maria De Santis has been a study coordinator and principal investigator of several Phase I–III trials and she is also involved in study protocol development for all genitourinary cancers.

She is a member of a number of national and international professional organisations including the European Organisation for Research and Treatment of Cancer, European Society of Medical Oncology, European Association of Urology (member of the guidelines office board, scientific office board) and American Society of Clinical Oncology and has served as a scientific committee member in these societies for the last years. Maria De Santis has committed herself to several guideline groups including the EAU Working Group on Muscle-invasive and Metastatic Bladder Cancer, S3 Guidelines for bladder cancer (Germany), the European Germ Cell Cancer Consensus Group and the International Consultation on Urological Diseases (testis cancer group, bladder cancer systemic treatment, upper urinary tract tumours, cytotoxic treatment) and has been a member in several consensus panels (testis-, prostate-, bladder-cancers). She is a reviewer for several international oncological and urological journals and has been editorial board member in urologic journals. Maria De Santis has published a number of original and review articles, editorials, letters, guidelines and book chapters.

Declaration of Interests
Scientific advisory boards: Amgen, Astellas, Bayer, Celgene, Dendreon, GSK, Janssen, OncoGenex/Teva, Pierre Fabre Oncology, Shionogi; Consultant, Speakers bureau: Amgen, Astellas, Bayer, Dendreon, GSK, Janssen, Novartis, OncoGenex/Teva, Pfizer, Pierre Fabre Oncology, Roche, Shionogi; Research Support: Pierre Fabre Oncology

Gastrointestinal tumors

J. Tabernero

Barcelona, Spain

tabernero

Current Positions and Research Interests
Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology. He is very actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies. He is especially devoted to phase I and II studies with pharmacodynamic endpoints with novel agents directed to the membrane receptors, like the EGFR-family and IGF-1R, the PI3K and ERK signalling pathways, as well as downstream cytoplasmatic and intranucleous effectors like Mdm2/p53 and aurora kinase.

Based in the idea that each tumor has an independent genetic identity, the group he is leading very actively participates in the development of molecular therapies targeting specific oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR or IGF1-R among others) for those patients displaying genetic lesions or pathway disregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments and to identify markers of primary resistance (de novo) and secondary treatment. At a preclinical level, the group he is leading is developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study the tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).

In addition, Dr. Tabernero is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), and different Editorial Boards including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer and Annals of Oncology. He has (co)authored approximately 250 peer-reviewed papers. He has also been member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.

Declaration of Interests
Consultant or advisory role: Amgen, Boehringer, Bristol-Myers Squibb, Genentech, Imclone, Lilly, Merck KGaA, Millennium, Novartis, Onyx, Pfizer, Roche, Sanofi, Celgene

Honoraria for presentations: Amgen, Merck KGaA, Novartis, Roche, Sanofi

A. Cervantes

Valencia, Spain

cervantes

Current Positions and Research Interests
Andrés Cervantes is Professor of Medicine at the University of Valencia and serves as Head of Section at the Dept. of Hematology and Medical Oncology in the Biomedical Research Institute INCLIVA. He got the Medical Oncology degree at the same institution in 1985. After completing his clinical training, he got a research fellowship at the Free University Hospital in Amsterdam, where he obtained in 1987 his PhD degree with a work on multidrug resistance in the Cellular Pharmacology Lab of this institution. His main areas of research are gastrointestinal and gynaecologic malignancies, phase I trials and new drug development. He has authored many research articles and educational papers published in peer-reviewed journals. He is also the Editor of Cancer Treatment Reviews. He is currently member of the ESMO Executive, as well as of the Educational Steering Committee. He is chairing the Clinical Practice Guidelines Working Group at ESMO. He devotes a significant amount of time to teaching, professional training, and continuing medical education.

Declaration of Interests
Dr Cervantes has acted as a consultant or advisor to Amgen, Astra Zeneca, Sanofi-Aventis, Merck Serono, MSD, Genentech, and Roche.

Breast tumors

F. André

Villejuif, France

Andre

Current Positions and Research Interests Fabrice André is a medical oncologist working at the Gustave Roussy Institute, Villejuif, France. He is involved in the development of targeted agents in breast cancer including mTOR inhibitors, FGFR inhibitors, PI3K inhibitors, CHK1 inhibitors. He is leading several academic prospective clinical trials that aim at developing personalized medicine for cancer treatment. He is also interested in symptoms management and chairs a large epidemiological cohort of 20 000 women with breast cancer. In addition to his clinical research activity, he is chairing a translational research unit focused on biomarker development in several disease area. He has published more than 150 articles or book chapters.

Declaration of Interests
In the past 2 years, participation in advisory boards, and/or speaker at meetings, and/or recipient of travel support for participation in medical meetings for/from: Astellas, AstraZeneca, EOS, Novartis, Pfizer, Servier.

C. Sotiriou

Brussels, Belgium

Sotirou

Current Positions and Research Interests
Dr. Christos Sotiriou earned a medical degree from the Medicine Faculty of the Université Libre de Bruxelles, Belgium, in 1993. He did his internal medicine/oncology residency at the Institut Jules Bordet (Profs. J. Klastersky, M. Piccart), and he earned his specialty in this field in July 1999. From October 1999 till September 2001, he worked as basic research fellow, at the Division of Clinical Sciences, National Cancer Institute (Pr Edison Liu), National Institutes of Health, Bethesda, MD, USA. After having completed a PhD Thesis at the Université Libre de Bruxelles in September 2004, he became “Chercheur Qualifié” (Research Faculty Member – tenured position) at the National Foundation for Scientific Research (FNRS, Belgium) in 2005. In March 2010, he took over the lead of the Breast Cancer Translational Research Laboratory J-C Heuson. In October 2013, he was appointed “Maître de Recherche” (Senior Research Associate – tenured position) by the National Foundation for Scientific Research (FNRS, Belgium). Dr. Sotiriou is “Chef de Clinique” (Head of clinic), since October 2013, at the Medical Oncology Clinic of the Institut Jules Bordet.

Declaration of Interests
Patent on gene expression signatures. In the past 2 years, participation in advisory boards, and/or speaker at meetings, and/or recipient of travel support for participation in medical meetings for/from (in alphabetical order): Amgen, Astellas, AstraZeneca, Bayer, Celgene, Nanostring Technologies, Novartis, Pfizer, Roche.

Thoracic tumors

T. Mitsudomi

Osaka, Japan

Mitsudomi

Current Positions and Research Interests
Dr. Mitsudomi received his medical degree from Kyushu University, Fukuoka, Japan in 1980, and subsequently completed his residency training in Surgery at Kyushu University Hospital. Dr. Mitsudomi completed his PhD in 1986 and was a visiting fellow at the National Cancer Institute-Navy Medical Oncology Branch, Bethesda, Maryland, USA, from 1989 to 1991. After working at University of Occupational and Environmental Health (1991-1994) and Kyushu University as an associate professor (1994-1995), Dr. Mitsudomi moved to Aichi Cancer Center in 1995 where he was a Vice Director of the hospital and a Chief of the Department of Thoracic Surgery. In 2012, Dr. Mitsudomi became a Professor at the Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan. His current research interests include surgical treatment of lung cancer and individualized treatment of lung cancer based on cancer genotypes such as EGFR mutations or ALK translocations. He has published more than 250 papers that have featured in international peer-reviewed journals. He is a recipient of Shinoi-Kawai Award from the Japan Lung Cancer Society (2001), JCA–Mauvernay Award from the Japanese Cancer Association (2005) and Mary Matthews Award from the International Association of Study of Lung Cancer (2013).

Declaration of Interests
Advisory board: AstraZeneca, Novartis, Chugai, Boehringer-Ingeleheim, Pfizer, Roche, Synta, Lecture fees: AstraZeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Eli-Lilly, Research support: AstraZeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Ono, Daiichi-Sankyo, Eli-Lilly

J. F. Vansteenkiste

Leuven, Belgium

vansteenkiste

Current Positions and Research Interests
Johan F Vansteenkiste graduated in 1982 from the Catholic University of Leuven before becoming a board-certified specialist in Internal Medicine and Pulmonology. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD in Leuven in 1996. He is head of the Respiratory Oncology Unit and its Clinical Trial Unit since 1995, and full professor at the Faculty of Medicine in Leuven. He is active member of different national and international societies such as ESMO, IASLC, ASCO, ERS, and others. He was Secretary of the Thoracic Oncology Assembly of the ERS and member of the ERS School Board from 2009-2012, member of the Board of Directors of IASLC in 2009-2013, and is member of the ESMO Lung Educational Group and Guidelines Group. He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He was associate editor for Respiration and Journal of Thoracic Oncology, and is reviewer for several oncology journals. He is author or co-author of more than 200 peer-reviewed papers and book chapters on Respiratory Oncology.

Declaration of Interests
Professor Vansteenkiste has acted as a consultant for Merck-Serono, GSK-Bio, and Lilly Oncology.

Head and neck tumors

A. T. C. Chan

Shatin, Hong Kong

chan

Current Positions and Research Interests
Anthony Chan, Li Shu Fan Medical Foundation Professor of Clinical Oncology, graduated from University College London in 1988 and received postgraduate training in the United Kingdom including the Royal Marsden Hospital where he developed a keen interest in multi-disciplinary clinical and translational research in solid cancers. He joined the Chinese University of Hong Kong in 1993 as Lecturer, becoming Department Chairman in 2002 and Professor of Clinical Oncology in 2006. He has been appointed Director of the Hong Kong Cancer Institute since 2002, Director of the Sir Yue-KongPao Centre for Cancer since 2003, Associate Director of the State Key Laboratory of Oncology in South China since 2006, Associate Dean for External Affairs since 2009, Chief Director of Phase I Clinical Trial Centre since 2013. He is Vice-President of the Hong Kong College of Physicians.

His research has focused on clinical and translational studies in Asia-prevalent cancers particularly in nasopharynx cancer. Professor Chan has conducted pivotal studies in multimodality treatment approaches in nasopharynx cancer, developed the clinical application of the biomarker EBV DNA and pioneered immunotherapeutic and targeted therapeutics in this disease. He published over 230 peer-reviewed papers, 40 book chapters and reviews, and delivered over 130 international lectures. He has served on the Editorial Board of the Journal of Clinical Oncology and is currently on the Editorial Boards of International Journal of Cancer, Cancer Science, Oral Oncology and the Chinese Journal of Cancer. He is Faculty member of Oncology, F1000Prime. In January 2014, he will serve as Associate Editor for Annals of Oncology.

Declaration of Interests
Professor Chan holds no shares in any drug company or in mutual funds investing exclusively in pharma. He has received study grants from and participated in advisory boards for Amgen, AstraZeneca, Bayer Schering, Boehringer Ingelheim, Eli Lilly, Merck Serono, Novartis, Pfizer, Roche, Sandoz, Sanofi.

Gynecological tumors

S. Pignata

Naples, Italy

Pignata

Current Positions and Research Interests
Sandro Pignata was born in Naples in 1962. He took the MD degree in 1986 at the Naples University and the PhD degree in Gastroenterological Science at the University of Rome in 1990. Since 1993 he is in Staff at the National Cancer Institute in Naples, where now is the chief of the Uro-Gynecological Department. Dr. Pignata is the president of the Multicenter Italian Trial in Ovarian cancer (MITO) group that is involved in several randomized trials on the treatment of gynaecological cancer, whose results have been published in important international journals. He is member of the educational committee of ESMO and of the executive board of the European Network of Gynaecological Oncological Trial Groups (ENGOT) and of the Gynecologic Cancer InterGroup (GCIG).

Declaration of Interests
Dr Pignata has received honoraria from Roche, GSK, Astra Zeneca, MSD, Pharmamar

Melanoma

C. Robert

Villejuif, France

Robert

Current Positions and Research Interests
Caroline Robert, M.D., Ph.D. is the Head of the Dermatology Service at Gustave Roussy Cancer Campus and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. She trained at the Paris V University, France and completed a research fellowship at Harvard, Brigham & Women’s hospital in Cancer Immunology and Immunotherapy. She is melanoma board secretary for the European Organization for the Research and Treatment of Cancer (EORTC), board member for the European Association of Onco-Dermatology (EADO), a member of the European Association of Dermato-Venereology (EADV) and the French society of Dermatology and Venereology. Her main focus of interest are clinical and translational Research on Melanoma: immunotherapy and targeted therapy, as well as the study of the cutaneous adverse events of anticancer agents. She is national and international coordinator of many clinical trials of targeted therapy and immunotherapy for melanoma patients, from phase I to III. Dr Robert is frequently invited to speak at international scientific meetings like the American Association of Medical Oncology or the American Association of Clinical Research. She has authored more than 120 articles in peer-reviewed scientific journals, including a number of publications on new treatments for metastatic melanoma.

Her recent work has focused on identification of new biomarkers for immunotherapy and targeted therapies of patients with melanoma.

Declaration of Interests
Caroline Robert has participated as principal investigator in several clinical trials sponsored by pharmaceutical companies and is occasionally participating in advisory boards for BMS, Merck, Roche, GSK, Amgen, Novartis.

Hematological malignancies

K. Tsukasaki

Kashiwa, Japan

tsukasaki

Current Positions and Research Interests
Dr Tsukasaki has a Medical Doctor degree (1984) and,after learning Hematology and late effect of atomic bombing,a Doctor in Medicine degree from Nagasaki University (1995). He was a research fellow at Cedars Sinai Medical Center in Los Angeles. He was a member of ATL (Adult T-cell leukemia-lymphoma)Preventing Program which consisted of screening pregnant women for anti-HTLV-1 Ab and recommending the HTLV-1 positive women refraining from breast feeding in Nagasaki prefecture. Hewas the primary investigator of the International Consensus Report on the management of ATL. Currently he is the Chief of the Hematology Department of the National Cancer Center Hospital East and Chairman of the Lymphoma Study Group of Japanese Clinical Oncology Group (JCOG).His specialties and research interests include Cancer Clinical Trials, Multi-Step Leukemogenesis including Viral Leukemogenesis, Molecular Targeting Therapy and Tumor Immunology.

Declaration of Interests
Participated in trials sponsored Roche by pharmaceutical companies as Kyowa-Hakko/Kirin, GlaxoSmithkline, Celgene, Rosch and MundyPharma; served on advisory boards of Takeda Bio.

P. L. Zinzani

Bologna, Italy

Zinzani

Current Positions and Research Interests
Professor Pier Luigi Zinzani receivedhis medical degree from the Faculty of Medicine and Surgery, and the Specialization in Hematology with honours at the University of Bologna. Awarded a Post-Doctoral Fellowship in Medical Physics released by the “Roger Williams Cancer Ospitale” of Providence (USA). Pier Luigi Zinzani is Associate Professor of Hematology at the Institute of Hematology “L. e A. Seràgnoli” at the University of Bologna. He is a member of the Italian Society of Hematology, the Italian Society of Experimental Hematology, the American Society of Hematology and American Society of Clinical Oncology and has presented his research at more than 200 national and international meetings (including ASH 2012 Education Program as speaker). Professor Zinzani is head of the Lymphoma Group Foundation in Italy. He has written more than 374 refereed articles in peer-reviewed journals. His current research interest includes clinical trial methodology, prognostic factors in NHL, Hodgkin’s disease, chronic lymphocytic leukemia, new drugs development, and hairy cell leukemia.

Declaration of Interests
He holds no shares in any drug company or in mutual funds investing exclusively in pharma. He has received study grants, honoraria for consultancy and/or is on the speaker bureau of Bayer Schering, Celgene, GSK, JNJ, Pfizer, Roche, Sandoz, Sanofi, Eli Lilly, Biogen Idec, Gilead, Pharmamar, Spectrum, Mundipharma, Kyowa Hakko Kirin Pharma, Takeda Millennium.

Supportive care

K. Jordan

Halle, Germany

Jordan

Current Positions and Research Interests
Dr. Karin Jordan graduated from Martin Luther University of Halle-Wittenberg, Germany, after internships at the University of California, San Diego and the University of Newcastle. Following a number of posts at the University Hospital, Halle, and Bernward Hospital, Hildesheim, she specialised in internal medicine, Hematology/Oncology and Palliative Care. Since 2010 she is Associate Professor of Medical Oncology and Supportive Care in the Department of Oncology/Haematology at the University Hospital, Halle. Here she serves also as vice executive director of the ethics committee at the University of Halle. Dr Jordan was appointed as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel 2009 in Perugia, Italy, and the German Cancer Society Consensus Panel on paravasation induced by cytotoxic agents. She holds the co-chair of the Supportive Care study group within the German Society of Medical Oncology (AIO) and is the associate chair of the German Association of Supportive Care in Oncology, Rehabilitation and Social Medicine (ASORS). Dr. Jordan is also a member of the ESMO Young Oncologist Committee. Since 2013 she is the national coordinator of the S3 Guidelines on Supportive Care within the Oncology Guideline Program of the German Cancer Society.

She has published more than 100 papers, reviews and book chapters mainly in the field of Supportive Care. Supportive Care remains her major interest with a special focus on antiemetic prophylaxis and treatment of chemotherapy induced nausea and vomiting and side effects of new drugs.

Declaration of Interests
Dr. Jordan holds no shares in any drug company. She has received study grants, honoraria for consultancy and/or is on the speaker bureau of MSD, Merck, Helsinn, Eisai, Amgen, Mundipharma, Pro-Strakan

Epidemiology

P. Boffetta

New York, New York, USA

boffetta

Current Positions and Research Interests
Dr. Boffetta received a Medical Degree from the University of Turin, Italy and a Master in Public Health from Columbia University in New York. Presently, he is Charles Bludhorn Professor of International Community Medicine, Director of the Institute for Translational Epidemiology, and Associate Director for Population Sciences of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai in New York, USA. He is also Adjunct Professor of Medicine at Vanderbilt Medical Center and the Vanderbilt-Ingram Cancer Center, and is Adjunct Professor of Epidemiology at Harvard School of Public Health. He is editor of 11 book and author of over 950 peer-reviewed scientific publications. Dr. Boffetta’s main fields of interest include cancer epidemiology and the risk related to tobacco, alcohol, diet, tobacco, and occupational or environmental exposures, molecular cancer epidemiology, and cancer prevention.

Declaration of Interests
Consultant to governmental agencies and private stakeholders on issues and projects on cancer epidemiology and prevention. Expert witness in litigation for plaintiffs and defendants.

Sarcoma and clinical pharmacology

O. Mir

Villejuif, France

Mir

Current Positions and Research Interests
Olivier Mir, MD, PhD, MPH is a medical oncologist and clinical pharmacologist in Gustave Roussy Cancer Institute, University of Paris-Sud. Dr. Mir trained as a medical oncologist and clinical pharmacologist at University Paris Descartes, and obtained the Silver medal (highest degree) from Paris Medical School in 2009. Dr. Mir is currently member of Breast and Sarcoma Groups at Gustave Roussy Cancer Institute in Paris, and is an active member of the French Sarcoma Group (GSF-GETO), Francilian Onco-Geriatry Group (FROG), EORTC Soft Tissue and Bone Sarcoma Group, and French Group on “Cancer in pregnancy” (CALG). His main research interests are: sarcoma/GIST, anti-VEGF agents, early drug development, pregnancy-related neoplasms, and geriatric oncology. He is also involved in translational research aspects related to precision medicine and pharmacokinetics notably in sarcoma/GIST, and pregnancy-related neoplasms (INSERM unit CIC-P 0901, Prof JM Treluyer, Paris Descartes University). Dr. Mir has contributed to over 100 peer-reviewed medical publications.

Declaration of Interests
Dr. Mir has acted as a consultant/speaker for Astra-Zeneca, Bayer, GSK, Novartis, Pfizer, Roche and Servier.

Early drug development

Jean-Charles Soria

Villejuif, France

Soria

Current Positions and Research Interests
Jean-Charles Soria is a Professor of Medecine and Medical Oncology at South-Paris University. He is a tenure-track and full-time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012.

Professor Soria is currently Chair of Drug Development Depatment at Gustave Roussy Cancer Center in Paris and is a member of the lung cancer unit with a focus on targeted therapies. His main research interests are: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medecine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria was a member of ESMO Executive Committee from 2008 to 2009, and has served as an ASCO committee member since 2006. He was the scientific chairman of the ECCO-ESMO 2011 meeting that was held in Stockholm in 2011. He has contributed to over 340 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology. He has been appointed as Editor in Chief of Annals of Oncology for the period 2014-2018.

Declaration of Interests
Professor Soria has acted as a consultant for AstraZeneca, Amgen, GSK, EOS, Sanofi, Servier Genentech, Roche, Novartis and Lilly.

Preclinical and experimental science

T. U. E. Helleday

Stockholm, Sweden

helleday

Current Positions and Research Interests
Thomas Helleday is the Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden heading the division of Translational Medicine and Chemical Biology located at Science for Life laboratories. Thomas Helleday started his own independent research groups at the Institute for Cancer Studies, University of Sheffield, UK in 2000, only a year after completing a PhD in Genetic Toxicology and a separate BSc in Business Administration and Economics. At the age of 35 years old he was already installed as professor at three Universities; Stockholm University, University of Sheffield and at the University of Oxford.

Professor Helleday heads a multidisciplinary translational research group focusing on understanding basic DNA repair and DNA-damage signaling pathways at replication forks and developing novel drugs for anti-cancer treatments. The group was first to demonstrate a novel concept for treating cancer called “synthetic lethality” established by the selective killing of BRCA mutated breast and ovarian cancers by PARP inhibitors. The research group is currently divided into teams focusing on basic science, biology, biochemistry, in vitro assays, medicinal chemistry and in vivo pharmacology. The work is focussed on bench to bedside and the group motto is ‘turning cancer defects into cures’. Professor Helleday has been awarded numerous eminent international grants and awards in recognition of his research accomplishments including the Eppendorf-Nature Young European Investigator Award (2005) for outstanding contribution within the field of biomedical science by the journal Nature and the prestigious ERC advanced grant (2010). He is currently been awarded a total of about EUR 15 million in research grants.

Declaration of Interests
Dr Helleday has declared no conflicts of interest.

Precision medicine

C. Swanton

London, UK

Swanton

Current Positions and Research Interests
Professor Swanton completed his PhD in 1998 at the Imperial Cancer Research Fund Laboratories on the UCL MBPhD programme before completing his medical oncology and Cancer Research UK funded post-doctoral clinician scientist training in 2008. Charles was appointed Medical Research Council and Cancer Research UK senior clinical research fellow and Group Leader of the Translational Cancer Therapeutics laboratory at the CR-UK London Research Institute in 2008 focussing on personalised cancer medicine through an understanding of mechanisms of drug resistance, intratumour heterogeneity and genomic instability. He combines his laboratory research with clinical duties focussed on biological mechanisms of drug resistance in lung and breast cancer.

Charles worked as a consultant medical oncologist at the Royal Marsden Hospital with an interest in early phase drug development for the treatment of specific subtypes of metastatic solid tumours (2008-2011). Charles has had lead and corresponding author publications in Nature, Cancer Cell, PNAS, Lancet Oncology and The New England Journal of Medicine. Charles is a member of several translational research scientific committees including the Cancer Research UK Sciences Committee and ESMO translational working group. He leads the scientific aspects of the EU Framework Program 7 PREDICT consortium. According to Thomson Reuters, his paper in NEJM in 2012 was the most highly cited in biomedicine in 2012. Charles was made Fellow of the Royal College of Physicians in April 2011 and was appointed to the Chair in Personalised Cancer Medicine at the University College London Cancer Institute and Consultant Medical Oncologist at UCL Hospitals, Thoracic Oncology Unit in November 2011. Charles is the Chief Investigator of the CR-UK TRACERx national lung cancer evolution study to decipher clonal evolution through the disease course and is director of the CR-UK UCL Lung Cancer Centre. Charles was recently promoted to the tenured position of Senior Group Leader at the CR-UK London Research Institute and was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013.

Declaration of Interests
Professor Swanton has acted as a consultant or speaker at meetings in the past 2 years for Astellas, Boehringer Ingelheim, Novartis, Sanofi Aventis and Ventana.

Bioinformatics

M. Delorenzi

Lausanne, Switzerland

delorenzi

Current Positions and Research Interests
Born 1960 in Lugano, Switzerland, Mauro Delorenzi studied molecular biology at Zürich University until a PhD (1990). After a long parenthesis in teaching, he obtained a M.Sc degree in statistics (2000) and moved to bioinformatics. He worked as postdoctoral researcher for genomic data mining at the Walter and Eliza Hall Institute in Melbourne, Australia (1999-2002). He developed a prediction model for the detection of sequences with the potential to form coiled-coil domains (MARCOIL) has been a state-of-the-art prediction tool for the last 10 years and other applications of hidden Markov models for the identification of sequence motifs in biological sequences.

Since 2003, Dr. Delorenzi is affiliated as group leader to the SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland and since 2013 he is also affiliated with the Ludwig Center for Cancer Research at the University Lausanne. He heads a bioinformatics core facility that specialized in bioinformatics, biostatistics and genomics expertise for biomedical research projects. He has since coauthored more than 80 scientific publications, many assessing prognostic / predictive markers and cancer subtypes, and has been a regular manuscript reviewer for several international journals.

Declaration of Interests
Bioinformatics support for projects: Merck-Serono, Novartis, Pfizer. Occasional participation to advisory meetings: Pfizer, Bayer, Ipsogen, Sanofi-Aventis. Occasional invited speaker: Ipsogen, Pfizer.

BioTechnologies

E. Mardis

St. Louis, Missouri, USA

Mardis

Current Positions and Research Interests
Dr. Elaine Mardis graduated Phi Beta Kappa from the University of Oklahoma with a B.S. degree in zoology. She then completed her Ph.D. in Chemistry and Biochemistry in 1989, also at Oklahoma. Following graduation, Dr. Mardis was a senior research scientist for four years at BioRad Laboratories in Hercules, CA. In 1993, Dr. Mardis joined The Genome Institute at Washington University School of Medicine. As Director of Technology Development, she helped create methods and automation pipelines for sequencing the Human Genome. She currently orchestrates the Center’s efforts to explore massively parallel sequencing technologies and to transition them into production sequencing capabilities as well as new applications.

Dr. Mardis has research interests in the application of DNA sequencing to characterize cancer genomes and transcriptomes, and using these data to support therapeutic decision-making. She also is interested in facilitating the translation of basic science discoveries about human disease into the clinical setting. Dr. Mardis serves as an editorial board member of Molecular Cancer Research, Genome Research and Molecular Oncology, and acts as a reviewer for Nature, the New England Journal of Medicine, Cell and Genome Research.She serves on the scientific advisory boards of DNA Nexus. Dr. Mardis received the Scripps Translational Research award for her work on cancer genomics in 2010, and was named a Distinguished Alumni of the University of Oklahoma College of Arts and Sciences for 2011. She is the former chair of Basic and Translational Sciences for the American College of Surgeons Oncology Group (ACOSOG).

Declaration of Interests
Dr Mardis has declared no conflicts of interest.

Onco-Immunology

G. Coukos

Lausanne, Switzerland

coukos

Current Positions and Research Interests
Professor George Coukos is Director of the Department of Oncology at the CHUV and Director of the service of Developmental Therapeutics. He is also the Director of the Ludwig Cancer Research Center in Lausanne, Switzerland. He was previously the Celso Ramon Garcia Professor and Associate Chief of the Division of Gynecologic Oncology, and Director, Ovarian Cancer Research Center, at the University of Pennsylvania Abramson Cancer Center. He is a recognized global leader in ovarian cancer immunotherapy and tumor microenvironment research. His research focuses on understanding the immune system's response to ovarian cancer and other tumor types, and on developing therapies, which enhance that response. He is also developing tools to target the tumor vasculature. Professor Coukos has received over 20 awards for his work on ovarian cancer immunology and immunotherapy. He has over 170 publications, and has maintained funding from the US National Cancer Institute and National Institutes of Health for over 10 years.

Professor Coukos has made many scientific contributions in the field of tumor immunology and immunotherapy. Professor Coukos also has extensive experience in designing and conducting phase I clinical cell-based immunotherapy studies, and in the development of cell-based immunotherapy from the laboratory to the clinic. He has functioned as the principal investigator and regulatory sponsor of 7 pilot or phase-I clinical immunotherapy studies in ovarian cancer at the University of Pennsylvania, using cell-based vaccines or adoptive T cell transfer manufactured at the University of Pennsylvania Cell and Vaccine Production Facility. Dr Coukos and his team provided crucial help in the development of the Standard Operating Procedures (SOPs) for these trials. Furthermore, they have extensive experience with submitting Investigational New Drug (IND) applications to the US Food and Drug Administration (FDA). Professor Coukos’ laboratory has also developed antibodies against the tumor vasculature, which are being prepared for clinical applications.

Declaration of Interests
Dr Coukos has declared no conflicts of interest.

Statistics

M. Buyse

Brussels, Belgium

Buyse

Current Positions and Research Interests
Marc Buyse holds a ScD in biostatistics from the Harvard School of Public Health (Boston, MA). He worked at the EORTC in Brussels and at the Dana Farber Cancer Institute in Boston. He is the founder of the International Drug Development Institute (IDDI) and of CluePoints, two biostatistical service organizations based in the US and Europe. Marc’s research interests include clinical trial design, validation of biomarkers and surrogate endpoints, statistical methods in oncology, statistical detection of errors and meta-analysis (http://publicationslist.org/marc.buyse).

Declaration of Interests
Dr Buyse is an employee of IDDI (International Drug development Institute), Inc. He holds stock in the private companies IDDI and CluePoints.

Molecular and surgical pathology

I. I. Wistuba

Houston, Texas, USA

Wistuba

Current Positions and Research Interests
Ignacio I. Wistuba, M.D., is Professor and Chair of the Department of Translational Molecular Pathology, Division of Pathology & Laboratory Medicine, M.D. Anderson Cancer Center at Houston, Texas, United States. He is also Professor of Thoracic/Head and Neck Medical Oncology and Director of the Thoracic Molecular Pathology Laboratory. Dr. Wistuba earned his medical degree in 1985 from the Austral University of Chile in Valdivia and trained in surgical pathology in the Catholic University of Chile in Santiago. He furthered his training in the United States at The University of Texas Southwestern Medical Center as a postdoctoral fellow in lung cancer molecular pathology research at the Hamon Center for Therapeutic Oncology Research Center. In 2003, he joined MD Anderson as Associate Professor of Pathology and Thoracic/Head and Neck Medical Oncology. In 2008 he was promoted to Professor, in 2010 was named the Jay and Lori Eisenberg Professor, and in 2013 named Anderson Clinical Faculty Chair for Cancer Treatment and Research.

Dr. Wistuba is a specialist in lung cancer surgical and molecular pathology. He has a strong record of scientific achievement in the study of lung cancer, which includes more than 300 peer-reviewed papers and several book chapters. His research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for targeted therapy. His research is funded by grants from NIH/NCI, Cancer Prevention Research Institute of Texas (CPRIT), V Foundation and the U.S. Department of Defense in addition to research agreements with pharmaceutical and biotechnology companies. Dr. Wistuba oversees biomarker studies for lung cancer therapeutic clinical trials, including the MD Anderson BATTLE program, and he is leader of the MD Anderson Cancer Center Support Grant (CCSG) Tissue Biorepository and Pathology Resources (TBPR).

He currently serves as the pathologist of the Lung Cancer Committee for the Southwestern Oncology Group (SWOG), the Lung Cancer Mutation Consortium (LCMC), and member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC). He is also member of the American Association of Oncology (ASCO) Research Committee. He serves as senior editor of Cancer Prevention Research and on the Editorial Boards of Clinical Cancer Research, Annals of Diagnostic Pathology, Archives of Pathology and Laboratory Medicine, and the Journal of Clinical Oncology.

Declaration of Interests
Dr. Wistuba is currently conducting research sponsored by Genentech, Inc., Myriad, Inc., Oncoplex, Merck, and Bayer. He has also received honoraria from GlaxoSmithKline, Genentech/Roche, Ventana, General Electric, Pfizer, Boehringer-Ingelheim, and Lilly.

EDITORS EMERITI:

F. Cavalli

Bellinzona, Switzerland

D. J. Kerr

Oxford, UK

J. B. Vermorken

Edegem, Belgium

EDITORIAL BOARD:

I. Abraham, Tucson, Arizona, USA
Y. Ando, Nagoya, Japan
P. Autier, Lyon, France
J. Baselga, New York, USA
J. Bellmunt, Boston, Massachusetts, USA
P. Bierman, Omaha, Nebraska, USA
C. Bokemeyer, Hamburg, Germany
N. Boku, Kawasaki, Japan
M. Boniol, Lyon, France
P. Bossi, Milan, Italy
E. Bria, Verona, Italy
P. G. Casali, Milan, Italy
K. N. Chi, Vancouver, Canada
F. Ciardiello, Naples, Italy
A. S. Coates, Sydney, Australia
A. Comandone, Turin, Italy
J. M. Connors, Vancouver, Canada
D. Cunningham, Sutton, UK
G. Curigliano, Milan, Italy
S. Delaloge, Villejuif, France

A. Di Leo, Prato, Italy
T. Dorff, Los Angeles, California, USA
H. Dosaka-Akita, Sapporo, Japan
L. H. Einhorn, Indianapolis, Indiana, USA
E. A. Eisenhauer, Kingston, Canada
A. Eniu, Cluj-Napoca, Romania
B. Escudier, Villejuif, France
C. Ferté, Villejuif, France
R. I. Fisher, Rochester, New York, USA
A. J. Gelderblom, Leiden, The Netherlands
G. Giaccone, Bethesda, Maryland USA
B. Glimelius, Uppsala, Sweden
B.-C. Goh, Singapore, Singapore
A. Goldhirsch, Milan, Italy
M. D. Green, Parkville, Australia
D. G. Haller, Philadelphia, Pennsylvania, USA
W. Hiddemann, Munich, Germany

I. Hyodo, Tsukuba, Japan
H. Iwata, Aichi, Japan
F. Janku, Houston, Texas, USA
N. Katsumata, Kawasaki, Japan
S. B. Kaye, Sutton, UK
U. Keilholz, Berlin, Germany
K. Kiura, Okayama, Japan
C.-H. Köhne, Oldenburg, Germany
P. A. Kosmidis, Athens, Greece
N. Kiyota, Kobe, Japan
P. N. Jr Lara, Sacramento, California, USA
C. La Vecchia, Milan, Italy
S. Loi, Melbourne, Australia
S. Loibl, Neu-Isenburg, Germany
P. Mauch, Boston, Massachusetts, USA
G. McArthur, Melbourne, Australia
D. Melisi, Verona, Italy
M. Middleton, Oxford, UK
H. Minami, Kobe, Japan
Y. Nishimura, Osaka-Sayama, Japan

K. Nishio, Osaka-Sayama, Japan
K. E. Öberg, Uppsala, Sweden
A. Ohtsu, Chiba, Japan
I. Okamoto, Fukuoka, Japan
M. Peeters, Edegem, Belgium
E. A. Perez, Jacksonville, Florida, USA
B. C. Pestalozzi, Zurich, Switzerland
G. J. Peters, Amsterdam, The Netherlands
P. Pfeiffer, Odense, Denmark
M. R. Posner, New York, USA
S. Postel-Vinay, Villejuif, France
A. Psyrri, New Haven, Connecticut, USA
D. Quinn, Los Angeles, California, USA
S. S. Ramalingam, Atlanta, Georgia, USA
M. Ranson, Manchester, UK
M. Reck, Grosshansdorf, Germany
B. Rini, Cleveland, Ohio, USA
R. Rosell, Badalona, Spain
A. D. Roth, Geneva, Switzerland

M. Scartozzi, Ancona, Italy
W. Scheithauer, Vienna, Austria
N. Schmitz, Hamburg, Germany
H.-J. Schmoll, Halle, Germany
H. C. Schouten, Maastrict, The Netherlands
I. Sekine, Chiba, Japan
S. T. Tagawa, New York, USA
S. Takahashi, Tokyo, Japan
V. Tjan-Heijnen, Maastricht, The Netherlands
S. Tjulandin, Moscow, Russian Federation
M. Toi, Kyoto, Japan
C. F. Verschraegen, Burlington, Vermont, USA
Y.-L. Wu, Guangzhou, China
J. C.-H. Yang, Taipei, Taiwan
S. Yano, Kanazawa, Japan
A. D. Zelenetz, New York, USA

EXECUTIVE EDITOR

Cancer Epidemiology Unit
University of Oxford
Richard Doll Building
Roosevelt Drive
OXFORD
OX3 7LF

Telephone:

+44 1865 289688

EDITORIAL OFFICE:

Via Luigi Taddei 4
CH-6962 Viganello-Lugano
Switzerland

Fax:

+4191 973 1909

Telephone:

+41 91 973 1908

Telephone:

+41 91 973 1910